3 / 3
Volume: 08
Research & Reviews: Journal of Medical & Health Sciences
Page 9
conference
series
.com
Diabetes Congress & Cancer summit 2019
December 04-05, 2019
December 04-05, 2019 | Tokyo, Japan
Asia Pacific Conference on
Diabetes Oncology
Necrotizing fasciitis as a rare documented side effect of Docetaxel
Introduction:
Docetaxel was frequently used to treat solid tumors, primarily breast cancer by disrupting microtubule function
to inhibit cell division. Although this agent was known to cause myalgia, arthralgia and neuropathy, there are few reports since
2005 that published the myositis complication of this agent. We presented a case report of necrotizing fasciitis as a continuing
myositis condition that happened a er Docetaxel treatment.
Case Report:
A 44 years old female diagnosed with stage-IIIB ductal invasive breast carcinoma (ER/PR+HER-). She underwent
chemotherapy with Docetaxel and Doxorubicin following the surgical treatment. A er 6th chemotherapy cycle, the patient
had pain at both thighs especially the le side. e symptom progressed until blisters seen on the skin and ulcer developed.
Physical examination showed normal vital signs, ulceration at posterior le thigh with minimal purulent discharge, sti
and tender on palpation. Laboratory result showed elevated CRP and ESR with no elevated WBC and shi ing of di erential
count. Doppler ultrasound showed so tissue edema with no sign of DVT or thrombus, contrast MRI showed thickening and
edema of the thigh muscle, enhancement of adductor brevis, semitendinosus, gluteus maximus and lateral vastus muscle,
which consistent with myositis necroticans. PET- CT revealed necrotic irregular pattern on subcutaneous tissue including
muscles at both posterior thigh compartment, with le domination. e result was di erent than previous PET- CT study
which conducted before administration of Docetaxel. She was suspected with myositis complicated with secondary infection
and planned to undergone surgical debridement. At intraoperative procedure, the surgeon found necrotic muscular tissue
with no sign of primary infection. e tissues were sent for pathology examination. Pathology examination revealed necrotic
tissues with gas inclusion, in ammatory cells (PMN and lymphocyte) and necrotic vascular tissues, these ndings consistent
with necrotizing fasciitis. In 1990s, reports of Docetaxel side e ect began to revealed myopathy condition with unexplained
pathophysiology. Documented cases of acute in ammatory myositis in patients treated with Docetaxel began to publish since
2005. Until 2015 there are less than 10 cases reported the myositis side e ect of Docetaxel. e proposed theory linking this
e ect were direct myotoxicity, systemic leakage of protein in the interstitial space, increased cytokine levels (primarily IL-6, IL-
8, IL-10), indirect muscle damage through hypocalcaemia and hyperthermia and accumulation of acid phosphatase in muscle
lysosome. Although Docetaxel induced myositis was an exclusion diagnosis, this rare side e ect must be considered to prevent
further deteriorating condition.
Discussion:
Myositis and necrotizing fasciitis is a rare side e ect of Docetaxel that only few of reports documented since 2005.
ere are several proposed mechanisms linking this condition. Consideration and early recognition of this condition were
needed to prevent further deterioration.
Biography
Jeffry Beta Tenggara has 8 years’ experience in treating oncology patients. He currently works in MRCCC Siloam Hospital Jakarta, a cancer hospital, as a medical
oncologist and a member of Internal Medicine Department. In addition to his medical practice, he is a member of the Indonesian Society of Internal Medicine,
Indonesian Society of Oncology, and Indonesian Medical Association.
jeffry.tenggara@yahoo.comJe ry Beta Tenggara
MRCCC Siloam Hospitals, Indonesia
Jeffry Beta Tenggara, RRJMHS 2019, ISSN: 2319-9865